Fibroblast growth factors and their receptors in urological cancers: Basic research and clinical implications

European Urology

Volumn 43, Issue 3, 2003, Pages 309-319

  Cronauer, M V ^a   Schulz, W A ^a   Seifert, H H ^a   Ackermann, R ^a   Burchardt, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Clinical implications; Fibroblast growth factors; Urological cancers

Indexed keywords

BINDING PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR; KERATINOCYTE GROWTH FACTOR;

BLADDER CANCER; CONFERENCE PAPER; HUMAN; KIDNEY CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TESTIS CANCER; URINARY TRACT CANCER;

EID: 0037337599     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00005-8     Document Type: Conference Paper

References (125)

1. Barritault D. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 1993; 150:1126-30.
2. Ravery V, Jouanneau J, Gil Diez S, Abbou CC, Caruelle JP, Barritault D, et al. Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol Res 1992;20:211-4.
3. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, et al. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 1997;31:223-33.
4. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 2000;60:4245-50.
5. Leung HY, Dickson C, Robson CN, Neal DE. Overexpression of fibroblast growth factor-8 in human prostate cancer. Oncogene 1996;12:1833-5.
6. Nanus DM, Schmitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993;85:1597-9.
7. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR, Fidler IJ. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994;145: 365-74.
8. Suzuki K, Tokue A, Kamiakito T, Kuriki K, Tanaka A. Predominant expression of fibroblast growth factor (FGF) 8, FGF4, and FGF receptor 1 in nonseminomatous and highly proliferative components of testicular germ cell tumors. Virchows Arch 2001;439: 616-21.
9. Granerus M, Welin A, Lundh B, Schofield PN, Ekstrom TJ, Engstrom W. Heparin binding growth factors and the control of teratoma cell proliferation. Eur Urol 1993;23:76-81.
10. Baird A, Böhlen P. Fibroblast growth factors. In: Sporn MB, Roberts AB, editors. Peptide growth factors and their receptors. I. New York: Springer; 1991. p. 368-418.
11. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986;128:475-84.
12. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocrine-Related Cancer 2000;7: 165-97.
13. Nishimura T, Nakatake Y, Konishi M, Ithoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000;1492:203-6.
14. Nakatake Y, Hoshikawa M, Asaki T, Kassai Y, Itoh N. Identification of a novel fibroblast growth factor, FGF-22, preferentially expressed in the inner root sheath of the hair follicle. Biochim Biophys Acta 2001;1517:460-3.
15. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-8.
16. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-7.
17. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992;6: 3362-9.
18. Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1992;1135:185-99.
19. Sano H, Forough R, Maier JAM, Case JP, Jackson A, Engleka K, et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990;110:1417-26.
20. Ichimura T, Maier JA, Maciag T, Zhang G, Stevens JL. FGF-1 in normal and regenerating kidney: expression in mononuclear, interstitial, and regenerating epithelial cells. Am J Physiol 1995; 269:F653-62.
21. Gabbianelli M, Sargiacomo M, Pelosi E, Testa U, Isacchi G, Peschle C. "Pure" human hematopoietic progenitors permissive action of basic fibroblast growth factor. Science 1990;249:1561-4.
22. Klagsbrun M, Folkman J. Angiogenesis. In: Sporn MB, Roberts AB, editors. Peptide growth factors and their receptors. II. New York: Springer; 1991. p. 549-86.
23. Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S, Kamidono S. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urol 1997;157:2351-5.
24. Duensing S, Grosse J, Atzpodien J. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anti-cancer Res 1995;15:2331-3.
25. Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, et al. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 2001;61:4229-37.
26. Yamanaka Y, Friess H, Buchler M, Berger HG, Uchida E, Onada M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993;53:5297-9.
27. Ornitz DM. FGFs, heparansulfate and FGFRs: complex interactions essential for development. Bioessays 2000;22:108-12.
28. Wu DQ, Kan MK, Sato GH, Okamoto T, Sato JD. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem 1991;266:16778-85.
29. Tassi E, Al-Attar A, Aigner A, Swift MR, McDonnell K, Karavanov A, et al. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem 2001;276:40247-53.
30. Gospodarowicz D. Localization of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974;249:123-7.
31. DiMario J, Buffinger N, Yamada S, Strohman RC. Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle. Science 1989;244:688-90.
32. Damon DH, Lobb RR, D'Amore PA, Wagner JA. Heparin potentiates the action of acidic fibroblast growth factor by prolonging its biological half life. J Cell Physiol 1989;138:221-6.
33. Bugler B, Amalric F, Prats H. Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Mol Cell Biol 1991;11:573-7.
34. Amalric F, Bouche G, Bonnet H, Brethenou P, Roman AM, Truchet I, et al. Fibroblast growth factor 2 (FGF-2) in the nucleus: translocation process and targets. Biochem Pharmacol 1994;47: 111-5.
35. McNeil PL, Muthukrishnan L, Warder E, D'Amore PA. Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989;109:811-22.
36. Vlodawsky I. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 1991; 16:268-71.
37. Imamura T, Engleka K, Zhan X, Tokita Y, Forough R, Roeder D, et al. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science 1990;249:1567-70.
38. Costa M, Danesi R, Agen C, DiPaolo A, Basolo F, Del Bianchi S, et al. MCF10A cells infected with int-2 oncogene induce angiogenesis in chick chorioallantoic membrane and rat mesentery. Cancer Res 1994;54:9-11.
39. Yoshida T, Ishimaru K, Sakamoto H, Yokota J, Hirohashi S, Igarashi K, et al. Angiogenic activity of the recombinant hst-1 protein. Cancer Lett 1994;83:261-8.
40. Schneeberger SA, Hjelmeland LM, Tucker RP, Morse LS. Vascular endothelial growth factor and fibroblast growth factor 5 are co-localized in vascular and avascular epiretinal membranes. Am J Ophtalmol 1997;124:447-54.
41. Gillis P, Salva U, Volpert OV, Jimenez B, Waters CM, Panos RJ, et al. Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. J Cell Sci 1999;112:2049-57.
42. Yoshimura S, Takagi Y, Harada J, Teramoto T, Thomas SS, Waeber C, et al. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proc Natl Acad Sci USA 2001;98:5874-9.
43. Cohn MJ, Izpisua-Belmonte JC, Abud H, Heath JK, Tickle C. Fibroblast growth factors induce additional limb development from the flank of chick embryos. Cell 1995;80:739-46.
44. Crossley PH, Minowada C, MacArthur CA, Martin GR. Roles for FGF8 in the induction, initiation, and maintenance of chick limb development. Cell 1996;84:127-36.
45. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, Mckeehan W. Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 1992;6:2123-8.
46. Thomson AA, Cunha GR. Prostatic growth and development are regulated by FGF10. Development 1999;126:3693-701.
47. Ichimura T, Finch PW, Zhang G, Kan M, Stevens JL. Induction of FGF-7 after kidney damage: a possible paracrine mechanism for tubule repair. Am J Physiol 1996;271:F967-76.
48. Ay I, Sugimori H, Finkelstein SP. Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents down-regulation of Bcl-2 in the ischemic brain following middle cerebral artery occlusion in rats. Brain Res Mol Brain Res 2001; 87:71-80.
49. Kondo S, Yin D, Aoki T, Takahashi JA, Morimura T, Takeuchi J. bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells. Exp Cell Res 1994;213: 428-32.
50. Shaulian E, Resnitzky D, Shifman O, Blandino G, Amsyterdan A, Yayon A, et al. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 1997;15:2717-25.
51. Song SH, Wientjes MG, Gan Y, Au JLS. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658-63.
52. Culig Z, Cronauer MV, Hobisch A, Bartsch G, Klocker H. Fibroblast growth factors and their receptors in metastases of prostate and other urological cancers. In: Jiang WG, Matsumoto K, Nakamura T, editors. Growth factors and their receptors in cancer metastasis. Dordrecht: Kluwer Academic Publishers; 2001. p. 93-106.
53. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001;15:1661-3.
54. Aigner A, Butscheid M, Kunkel P, Krause E, Lamszus K, Wellstein A, et al. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 2001;92:510-7.
55. Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002;21:5733-42.
56. Czubayko F, Smith RV, Chung HC, Wellstein A. Tumor growth and angiogenesis induced by a secreted protein for fibroblast growth factors. J Biol Chem 1994;269:28243-8.
57. Sauter ER, Nesbit M, Tichansky D, Liu Z-J, Shirakawa T, Palazzo J, et al. Fibroblast growth factor-binding protein expression changes with disease progression in clinical and experimental squamous epithelium. Int J Cancer 2001;92:374-81.
58. Liu X-H, Aigner A, Wellstein A, Ray PE. Up-regulation of a fibroblast growth factor-binding protein in children with renal diseases. Kidney Int 2001;59:1717-28.
59. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 1994;91:2890-4.
60. Isaacs JT, Coffey DS. Androgenic control of prostatic growth: regulation of steroid levels. UICC Monogr (Prostatic Cancer) 1979; 48:112-22.
61. Cronauer MV, Eder IE, Hittmair A, Sierek G, Hobisch A, Culig Z, et al. A reliable system for the culture of human prostatic cells. In Vitro Cell Dev Biol Anim 1997;33:742-4.
62. Thomson AA, Foster BA, Cunha GR. Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development 1997;124:2431-9.
63. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 overexpression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999;18:2755-61.
64. Dorkin TJ, Robinson MC, Marsh C, Neal DE, Leung HY. aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol 1999;189:564-9.
65. Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999;274:12827-34.
66. Metha PB, Robson CN, Neal DE, Leung HY. Serum keratinocyte growth factor measurement in patients with prostate cancer. J Urol 2000;164:2151-5.
67. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994;54:5474-8.
68. Planz B, Wang Q, Kirley SD, Marberger M, McDougal WS. Regulation of keratinocyte growth factor receptor and androgen receptor in epithelial cells of the human prostate. J Urol 2001;166: 678-83.
69. Cronauer MV, Stadlmann S, Klocker H, Abendstein B, Eder IE, Rogatsch H, et al. Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1β. Am J Pathol 1999;155:1977-84.
70. Giri D, Ittman M. Interleukin-1α is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2000;157:249-55.
71. Giri D, Ittman M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2: a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001;159:139-47.
72. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, et al. Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci USA 1992; 89:8928-32.
73. Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Härkönen PL. Increased expression of FGF-8 isoforms and FGF-8 receptors in human premalignant prostatic intraepithelial neoplastic lesions and prostate cancer. Lab Invest 2001;81:815-26.
74. Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 2000;60:6730-6.
75. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, et al. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res 1998;58:2053-6.
76. Gnanapragasam VJ, Robson CN, Neal DE, Leung HY. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 2002;21:5069-80.
77. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51: 3753-61.
78. Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer MK. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995;76:2304-11.
79. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61.
80. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G, et al. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 2000;82:39-45.
81. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-22.
82. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999;5:1063-71.
83. Matsubara A, Kan M, Feng S, Mckeehan WL. Inhibition of malignant rat prostate tumor cells by restauration of fibroblast growth factor receptor 2. Cancer Res 1998;58:1509-14.
84. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittman M. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 2001;93:1790-3.
85. Giri D, Ropiquet F, Ittman M. FGF-9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol 1999;180:53-60.
86. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991;117:144-50.
87. Klein RD, Maliner-Jongewaard MS, Udayakumar TS, Boyd JL, Nagle RB, Bowden GT. Promatrilysin expression is induced by fibroblast growth factors in the prostatic carcinoma cell line LNCaP but not in normal primary prostate epithelial cells. Prostate 1999;41:215-23.
88. Udayakumar TS, Klein RD, Maliner MS, Nagle RB, Bowden GT. Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors. Int J Cancer 2001;91: 187-92.
89. Zhang Y, Song S, Yang F, Au JL, Wientjes MG. Non-toxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 2001;299:426-33.
90. Jouannean J, Plouet J, Moens G, Thiery JP. FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo. Oncogene 1997;14:671-6.
91. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988; 48:2083-8.
92. O'Brien TS, Smith K, Cranston D, Fuggle S, Bicknell R, Harris AL. Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol 1995; 76:311-4.
93. Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993;85:241-2.
94. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res 1977;57:136-40.
95. Allen LE, Maher PA. Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J Cell Physiol 1993;155:368-75.
96. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:5365-9.
97. Yi ES, Shabaik AS, Lacey DL, Bedoya AA, Yin S, Housley RM, et al. Keratinocyte growth factor causes proliferation of urothelium in vivo. J Urol 1995;154:1566-70.
98. De Boer WI, Houtsmuller AB, Izadifar V, Muscatelli-Groux B, van der Kwast TH, Chopin DK. Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell - carcinoma cells. Int J Cancer 1997;71:284-91.
99. Diez de Medina SG, Chopin D, El Marjou A, Delouvee A, LaRochelle WJ, Hoznek A, et al. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene 1997;14:323-30.
100. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
101. Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 2001; 20:4416-8.
102. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9.
103. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-8.
104. Fujimoto K, Ichimori Y, Yamaguchi H, Arai K, Futami K, Ozono S, et al. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 1995;86:182-6.
105. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;58:735-43.
106. Yoshimura K, Eto H, Miyake H, Hara I, Arakawa S, Kamidono S. Messenger ribonucleic acids for fibroblast growth factors and their receptor in bladder and renal cell carcinoma cell lines. Cancer Lett 1996;103:91-7.
107. Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res 2001;61:5511-6.
108. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001;284: 977-81.
109. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98: 6500-5.
110. Yoshida T, Tsutsumi M, Sakamoto H, Miyagawa K, Teshima S, Sugimura T, et al. Expression of the HST1 oncogene in human germ cell tumors. Biochem Biophys Res Commun 1988; 155:1324-9.
111. Strohmeyer T, Peter S, Hartmann M, Munemitsu S, Ackermann R, Ullrich A, et al. Expression of hst-I and c-kit proto-oncogenes in human testicular germ cell tumors. Cancer Res 1991;51:1811-6.
112. Pertovaara L, Tienari J, Vainikka S, Partanen J, Saksela O, Lehtonen E, et al. Modulation of fibroblast growth factor receptor expression and signaling during retinoic acid-induced differentiation of Tera-2 teratocarcinoma cells. Biochem Biophys Res Commun 1993;191:149-56.
113. Yamazaki K, Nagao T, Yamaguchi T, Saisho H, Kondo Y. Expression of basic fibroblast growth factor (FGF-2)-associated with tumour proliferation in human pancreatic carcinoma. Virchows Arch 1997;431:95-101.
114. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
115. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-93.
116. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82:812-7.
117. Myers C, Cooper MR, LaRocca R, Walther MM, Weiss G, Choyke P, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992;10:881-9.
118. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993; 85:611-21.
119. Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, et al. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 1992;52:5775-9.
120. Walther MM, Figg WD, Linehan WM. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J Urol 1996;14(Suppl 1):S8-11.
121. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE, et al. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 1993;68:932-8.
122. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, et al. Suramin: an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994;54:2654-60.
123. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
124. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58: 808-14.
125. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 2000; 6:4422-31.